Empowered Funds LLC Invests $9.04 Million in Stryker Corporation $SYK

Empowered Funds LLC bought a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, Holdings Channel.com reports. The firm bought 28,726 shares of the medical technology company’s stock, valued at approximately $9,044,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. United Capital Financial Advisors LLC purchased a new stake in shares of Stryker in the second quarter valued at approximately $7,567,000. Dearborn Partners LLC acquired a new position in shares of Stryker during the second quarter worth about $20,476,000. Ruggaard & Associates LLC acquired a new stake in Stryker in the second quarter valued at $387,000. Equitable Holdings Inc. purchased a new position in shares of Stryker in the 2nd quarter valued at $5,366,000. Finally, Centaurus Financial Inc. purchased a new position in Stryker during the 2nd quarter worth approximately $325,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Barclays dropped their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective for the company. Finally, Royal Bank Of Canada reduced their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 2.9%

Shares of Stryker stock opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The business has a 50-day moving average of $329.10 and a 200-day moving average of $331.47. The company has a market capitalization of $127.08 billion, a PE ratio of 34.33, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.